Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5950 Priestly Dr CARLSBAD CA 92008-8849 |
Tel: | N/A |
Website: | https://www.internationalstemcell.com |
IR: | See website |
Key People | ||
Andrey Semechkin Co-Chairman of the Board, Chief Executive Officer | Donald Arthur Wright Independent Co-Chairman of the Board, CEO and President of SIS, Inc. | Russell Kern Executive Vice President, Chief Scientific Officer |
Business Overview |
International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market. |
Financial Overview |
For the fiscal year ended 31 December 2023, International Stem Cell Corp revenues decreased 5% to $7.8M. Net loss decreased 60% to $131K. Revenues reflect Biomedical market segment decrease of 4% to $6.9M, Anti-aging cosmetic market segment decrease of 12% to $923K. Lower net loss reflects Anti-aging cosmetic market segment loss decrease of 7% to $519K. |
Employees: | 29 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $6.97M as of Dec 31, 2023 |
Annual revenue (TTM): | $7.79M as of Dec 31, 2023 |
EBITDA (TTM): | -$0.47M as of Dec 31, 2023 |
Net annual income (TTM): | -$0.13M as of Dec 31, 2023 |
Free cash flow (TTM): | $0.85M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $1.87M as of Dec 31, 2023 |
Shares outstanding: | 8,004,389 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |